GUARDANT HEALTH INC
NASDAQ: GH (Guardant Health, Inc.)
Kemas kini terakhir: semalam, 10:02PM31.67
0.54 (1.73%)
| Penutupan Terdahulu | 31.13 |
| Buka | 30.69 |
| Jumlah Dagangan | 2,088,660 |
| Purata Dagangan (3B) | 1,770,053 |
| Modal Pasaran | 3,912,986,880 |
| Harga / Jualan (P/S) | 5.67 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | -74.02% |
| Margin Operasi (TTM) | -61.10% |
| EPS Cair (TTM) | -4.28 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.90% |
| Nisbah Semasa (MRQ) | 6.22 |
| Aliran Tunai Operasi (OCF TTM) | -254.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -151.07 M |
| Pulangan Atas Aset (ROA TTM) | -16.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -609.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Guardant Health, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.13 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.57% |
| % Dimiliki oleh Institusi | 105.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cadian Capital Management, Lp | 30 Sep 2024 | 6,930,474 |
| Parkwood Llc | 30 Sep 2024 | 2,800,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (JP Morgan, 57.88%) | Beli |
| 50.00 (Leerink Partners, 57.88%) | Beli | |
| Median | 43.00 (35.78%) | |
| Rendah | 35.00 (Bernstein, 10.52%) | Beli |
| Purata | 42.75 (34.99%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 25.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 07 Nov 2024 | 36.00 (13.67%) | Beli | 28.59 |
| JP Morgan | 07 Nov 2024 | 50.00 (57.88%) | Beli | 28.59 |
| Bernstein | 30 Oct 2024 | 35.00 (10.51%) | Beli | 23.07 |
| Leerink Partners | 17 Oct 2024 | 50.00 (57.88%) | Beli | 20.68 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |